: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

Chinese Coaching

Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Autoimmune Disorders

Free Subscription

Articles published in J Neurol
Retrieve available abstracts of 386 articles:
HTML format

Single Articles

December 2025

BSTEH G, Velez Escola L, Hegen H, Lindner E, et al
Application of optical coherence tomography in multiple sclerosis: consensus recommendations of the Austrian network (AN-OCT-MS).
J Neurol. 2025;273:24.
PubMed Abstract available

TEDONE N, Preziosa P, Meani A, Mistri D, et al
Clinical, functional and cognitive features of late-onset multiple sclerosis.
J Neurol. 2025;273:14.
PubMed Abstract available

ELLINGHAUS CA, Rohling HM, Dorsch EM, Sperber PS, et al
Anchor-based evaluation of digital motor biomarkers from a 2-year observation in 100 patients with multiple sclerosis.
J Neurol. 2025;273:4.
PubMed Abstract available

HEDSTROM AK, Olsson T, Alfredsson L
Determinants and prognostic value of onset symptoms in multiple sclerosis.
J Neurol. 2025;273:2.
PubMed Abstract available

November 2025

WANG Z, Li S, Liu J, Li Y, et al
Nomograms integrating cortical morphometric metrics with 3D multi-parametric MRI radiomics for predicting disability progression and cognitive worsening in relapsing-remitting multiple sclerosis: a multi-center validation study.
J Neurol. 2025;272:792.
PubMed Abstract available

KLEINSCHNITZ C, Skripuletz T, Pfeuffer S, Pawlitzki M, et al
Is therapy-free remission a realistic goal with cladribine tablets in multiple sclerosis? New insights into the mechanism of action and clinical implications of immune reconstitution with cladribine tablets in MS therapy.
J Neurol. 2025;272:788.
PubMed Abstract available

PIERVINCENZI C, Ojha A, Tommasin S, Satriano F, et al
Functional connectivity changes are associated with disability progression in multiple sclerosis: a longitudinal fMRI study.
J Neurol. 2025;272:787.
PubMed Abstract available

ARSLAN D, Colpak AI, Yardimci GK, Bulut EG, et al
Neurological involvement in IgG4-related disease: focus on neuro-ophthalmologic features.
J Neurol. 2025;272:785.
PubMed Abstract available

BALSHI A, Dempsey JP, Kumbar S, Manning N, et al
Motherhood and diagnostic delay among women with multiple sclerosis.
J Neurol. 2025;272:784.
PubMed Abstract available

YANG X, Li F, Zhe J, Zhang Z, et al
Single-cell RNA sequencing of cerebrospinal fluid immune cells in relapsing-remitting multiple sclerosis: insights into cellular composition and immune dynamics.
J Neurol. 2025;272:778.
PubMed Abstract available

TEDONE N, Grosselle M, Portaccio E, Amato MP, et al
The brief repeatable battery of neuropsychological test (BRB-N) version B: update of Italian normative data.
J Neurol. 2025;272:776.
PubMed Abstract available

MONSCHEIN T, Untersteiner H, Ponleitner M, Krajnc N, et al
Safety of disease-modifying therapies in multiple sclerosis: real-world data from the Austrian MS Treatment Registry (AMSTR).
J Neurol. 2025;272:774.
PubMed Abstract available

WANG R, Wang X, Shi Z, Kong L, et al
Severe attacks and worse prognosis in patients with late-onset neuromyelitis optica spectrum disorder highlight the need for early highly effective treatment.
J Neurol. 2025;272:771.
PubMed Abstract available

MARTIRE MS, Gattuso I, Vezzulli P, Guerrieri S, et al
Unveiling a silent threat: slowly expanding spinal cord lesion linked to clinical worsening in multiple sclerosis: a case report.
J Neurol. 2025;272:773.
PubMed

STEINER OL, Angela C, Krasivskaya E, Klostermann F, et al
Cognitive impairment in chronic inflammatory demyelinating polyneuropathy.
J Neurol. 2025;272:769.
PubMed Abstract available

LADEIRA F, Nobrega C, Cerqueira J
Correction: Evaluation of the efficacy of the SARS-CoV-2 vaccine additional and booster doses in immunocompromised patients with multiple sclerosis: the COVACiMS study.
J Neurol. 2025;272:768.
PubMed

MESSINA C
The overlooked side of myasthenia gravis: the non-motor manifestations-a comprehensive review.
J Neurol. 2025;272:764.
PubMed Abstract available

LI X, Gupta P, Paramasivan NK, Flanagan EP, et al
Development of anti-LGI1 autoimmune encephalitis outcome rating score using the Rasch analysis.
J Neurol. 2025;272:757.
PubMed Abstract available

TROJANO M, Iaffaldano P, Copetti M, Drahota J, et al
Big multiple sclerosis data network: novel modelling approaches for real-world data analysis.
J Neurol. 2025;272:754.
PubMed Abstract available

BARNETT-TAPIA C, Cortes Vicente E, Pascuzzi RM, Utsugisawa K, et al
Measuring the effect of rozanolixizumab using the Myasthenia Gravis Impairment Index: analyses from the randomized phase 3 MycarinG study.
J Neurol. 2025;272:752.
PubMed Abstract available

OZAKBAS S, Alizada S, Caliskan C, Simsek Y, et al
Familial multiple sclerosis is associated with accelerated progression to secondary progressive phase: a retrospective single-center cohort study.
J Neurol. 2025;272:749.
PubMed Abstract available

WASKOWIAK PT, de Jong BA, Uitdehaag BMJ, Myronenko A, et al
Cognitive awareness in people with multiple sclerosis before and after neuropsychological assessment.
J Neurol. 2025;272:748.
PubMed Abstract available

MATAS E, Bau L, Romero-Pinel L, Leon I, et al
Benign multiple sclerosis and long-term outcomes after 30 years.
J Neurol. 2025;272:747.
PubMed Abstract available

October 2025

TAN Y, Lu J, Zhang J, Qi X, et al
Efgartigimod-rituximab sequential therapy in Anti-NMDAR encephalitis: real-world evidence for a novel salvage-maintenance strategy.
J Neurol. 2025;272:739.
PubMed Abstract available

LI Y, Zhou Q, Dong X, Duan W, et al
Association between antibody status and exacerbation in patients with myasthenia gravis who achieved minimal manifestation or better status.
J Neurol. 2025;272:736.
PubMed Abstract available

MONTE G, Tiralongo G, Papetti L, Ferilli MAN, et al
Complete Epstein-Barr virus seropositivity in a cohort of pediatric onset multiple sclerosis: a comparison to other autoimmune diseases.
J Neurol. 2025;272:735.
PubMed Abstract available

PALAZZO L, Cetta I, Bongiovanni L, Gastaldi M, et al
Clinical and neuroradiological evolution of thymoma-associated anti-GABAA receptor autoimmune encephalitis: insights from a clinical case report.
J Neurol. 2025;272:733.
PubMed

HUA LH, Brown B, Camacho E, Chinea AR, et al
Switch from intravenous anti-CD20 therapy to subcutaneous ofatumumab in patients with relapsing MS: results from the OLIKOS study.
J Neurol. 2025;272:725.
PubMed Abstract available

ABOSEIF A, Jackson-Tarlton CS, Schwarz CG, Decker PA, et al
Cervical cord atrophy correlates with intracranial lesion burden in tumefactive multiple sclerosis.
J Neurol. 2025;272:717.
PubMed Abstract available

LATINI E, Guida M, Zirafa CC, Rizzo S, et al
Long-term effectiveness of thymectomy in late-onset myasthenia gravis.
J Neurol. 2025;272:714.
PubMed Abstract available

OPFER R, Spies L, Kruger J, Buddenkotte T, et al
Whole brain volume loss is associated with a short-term disability progression in relapse-activity free multiple sclerosis.
J Neurol. 2025;272:715.
PubMed Abstract available

SU X, Zheng Z, Yu F, Liu C, et al
The impact of different exercise types on cognitive function in patients with multiple sclerosis: a systematic review and network meta-analysis.
J Neurol. 2025;272:709.
PubMed Abstract available

PREZIOSA P, Brescia Morra V, Capobianco M, Gasperini C, et al
Efficacy and safety of ublituximab for relapsing multiple sclerosis patients: current evidence and expert opinion.
J Neurol. 2025;272:707.
PubMed Abstract available

LIU R, Kong L, Cao L, Wang H, et al
Retinal microvascular differences between multiple sclerosis and neuromyelitis optica spectrum disorder: a cross-sectional study with diagnostic modeling.
J Neurol. 2025;272:700.
PubMed Abstract available

BRIL V, Antozzi C, Berkowicz T, Druzdz A, et al
Self-administration of rozanolixizumab via manual push and infusion pump methods in patients with generalised myasthenia gravis: a randomised, phase 3, open-label, crossover study.
J Neurol. 2025;272:686.
PubMed Abstract available

TUNC A, Koc ER, Carnero Contentti E, Gomez Figueroa E, et al
Predictors of relapse and disability in NMOSD, MOGAD, and double-seronegative demyelinating syndromes: an international multicenter retrospective cohort study.
J Neurol. 2025;272:680.
PubMed Abstract available

AHMAD R, Jackson-Tarlton CS, Flanagan EP, Messina S, et al
Critical demyelinating lesions in progressive multiple sclerosis: a prospective observational study.
J Neurol. 2025;272:677.
PubMed Abstract available

September 2025

KO KY, Kazzi C, Seery N, Griffith S, et al
Subjective psychiatric symptoms in post-acute autoimmune encephalitis: findings from the Australian autoimmune encephalitis consortium.
J Neurol. 2025;272:665.
PubMed Abstract available

WAGSHUL ME, Nayak S, Foley FW, Motl RW, et al
Grey matter atrophy patterns of mobility shared across older adults with and without multiple sclerosis.
J Neurol. 2025;272:656.
PubMed Abstract available

YANG X, Jia Z, Lian X, Zhang R, et al
Ofatumumab treatment in patients with neuromyelitis optica spectrum disorder: a retrospective multicenter cohort study.
J Neurol. 2025;272:655.
PubMed Abstract available

ROMANO F, Rocca MA, Pagani E, Amato MP, et al
Effects of cognitive rehabilitation and exercise on brain structure in progressive multiple sclerosis: results from the CogEx trial.
J Neurol. 2025;272:645.
PubMed Abstract available

MORENO-NAVARRO L, Mora-Diaz S, Ruiz-Escribano-Menchen L, Sempere AP, et al
Kappa free light chain index as a diagnostic and prognostic biomarker in multiple sclerosis.
J Neurol. 2025;272:646.
PubMed Abstract available

HABEK M, Adamec I, Gabelic T, Barun B, et al
Diagnostic performance of the 2010, 2017, and 2024 McDonald criteria: clinical implications in multiple sclerosis.
J Neurol. 2025;272:637.
PubMed Abstract available

CHEN Y, Xie L, Cui H, Zhang Y, et al
Autoimmune encephalitis with Anti-mGluR1 antibodies: a comprehensive review.
J Neurol. 2025;272:623.
PubMed Abstract available

ALONI R, Dror C, Barazani T, Kalron A, et al
Wartime stress and relapse risk in people with multiple sclerosis: a prospective cohort study.
J Neurol. 2025;272:619.
PubMed Abstract available

ZHU W, Chen Y, Tian C, Wang J, et al
Factors associated with early response to efgartigimod in patients with generalized myasthenia gravis: a multicenter retrospective observational study.
J Neurol. 2025;272:622.
PubMed Abstract available

YANG J, Li H, Zhang Y, Hu S, et al
Effects of exercise on fatigue and quality of life in multiple sclerosis: a network meta-analysis and systematic review.
J Neurol. 2025;272:621.
PubMed Abstract available

JU Y, Geng C, Guan H
Initiation of tocilizumab within 24 hours in acute necrotizing encephalopathy is related to a good outcome: a systematic review.
J Neurol. 2025;272:618.
PubMed Abstract available

ELLENBERGER D, Frahm N, Stahmann A, Warnke C, et al
Age-related differences in switching highly effective disease-modifying therapy in patients with multiple sclerosis.
J Neurol. 2025;272:609.
PubMed Abstract available

ASLAN D, Bourabia S, Kowall B, Straukiene A, et al
The impact of autoimmune comorbidities on multiple sclerosis progression: insights from a longitudinal single-center study.
J Neurol. 2025;272:607.
PubMed Abstract available

KONG L, Tan X, Wang H, Cao L, et al
Progressive retinal and microvascular neurodegeneration in neuromyelitis optica spectrum disorders: a longitudinal SS-OCT/OCTA study.
J Neurol. 2025;272:606.
PubMed Abstract available

August 2025

KEVER A, Kang N, Meza C, Pogacar M, et al
Not for everyone: examining predictors of cognitive rehabilitation success in multiple sclerosis.
J Neurol. 2025;272:593.
PubMed

MATHEY G, Epstein J, Alix T, Julien M, et al
Cerebrospinal fluid levels of chitinase 3-like 1 and interleukin-6 can predict response to platform therapies in relapsing multiple sclerosis.
J Neurol. 2025;272:592.
PubMed Abstract available

ADAMMEK F, Gralla W, Kupjetz M, Rademacher A, et al
Functional exercise training in persons with multiple sclerosis: a systematic review.
J Neurol. 2025;272:590.
PubMed Abstract available

REEVES JA, Tranquille A, Bartnik A, Mohebbi M, et al
Paramagnetic rim lesions are associated with choroid plexus inflammation and expansion over 5 years in people with multiple sclerosis.
J Neurol. 2025;272:585.
PubMed Abstract available

SCANDIFFIO J, Langer LK, Senthilnathan V, Feng G, et al
Effects of psychological therapies in people with multiple sclerosis: a systematic review and network meta-analysis of randomized controlled trials.
J Neurol. 2025;272:584.
PubMed Abstract available

GUERRIERI S, Gattuso I, Genchi A, Nozzolillo A, et al
Stratify and ImmunoWELL JCV tests performances in a real-world multiple sclerosis cohort: possible clinical implications of biosimilar Natalizumab use.
J Neurol. 2025;272:583.
PubMed

ABBADESSA G, Maida E, Bonavita S, Lavorgna L, et al
First the B cells fall, then the T cells follow: temporal immunological shift with ocrelizumab in multiple sclerosis.
J Neurol. 2025;272:582.
PubMed Abstract available

SBAIHAT H, Roenneke K, Muller D, Ladopoulos T, et al
MRI-based human brain atlases of R1, R2, proton density, and myelin volume fraction using synthetic quantitative imaging at 1.5 T.
J Neurol. 2025;272:578.
PubMed Abstract available

JAWORSKI M 3RD, Balconi J, Santivasci C, Youngs M, et al
Improving conscientiousness through a smartphone app and telecoaching intervention: insights from multiple sclerosis and healthy aging samples.
J Neurol. 2025;272:580.
PubMed Abstract available

ALAM Z, Maddali A, Patel S, Weber N, et al
Current imaging applications, radiomics, and machine learning modalities of CNS demyelinating disorders and its mimickers.
J Neurol. 2025;272:568.
PubMed Abstract available

ALFREDSSON L, Guo J, Johansson E, Olsson T, et al
Early-life and adult body mass index in relation to MS disability progression.
J Neurol. 2025;272:571.
PubMed Abstract available

FILIPPI M, Amato MP, Centonze D, Gallo P, et al
The use of high-efficacy disease-modifying therapies in multiple sclerosis: recommendations from an expert Delphi consensus.
J Neurol. 2025;272:565.
PubMed Abstract available

JOHN N, Lim A, Sunthar SR, Zhang L, et al
Immunotherapies in neuromyelitis optica: Bayesian network meta-analysis.
J Neurol. 2025;272:563.
PubMed Abstract available

PETERSSON M, Wu J, Berggren F, Schager I, et al
Impact of disease activity on quality of life and EQ-5D-3L score in myasthenia gravis: results from the Swedish MG registry.
J Neurol. 2025;272:562.
PubMed Abstract available

LEITNER U, Chew SH, Blanch J, Viswanathan M, et al
Characteristics of MRI lesions in AQP4 antibody-positive NMOSD, MOGAD, and multiple sclerosis: a systematic review and meta-analysis.
J Neurol. 2025;272:560.
PubMed Abstract available

MANISCALCO GT, Sparaco M, Di Gregorio M, Cafasso G, et al
Real-world comparison of lymphopenia profiles in S1P receptor modulators for multiple sclerosis: a multicenter retrospective study.
J Neurol. 2025;272:559.
PubMed Abstract available

KERITAM O, Ascoli O, Harsanyi A, Cetin H, et al
Advanced multiple sclerosis: an exploratory study on a neglected patient population.
J Neurol. 2025;272:553.
PubMed Abstract available

CHEN Q, Ma Y, Li Z, Yu C, et al
Distributions and network changes of brain activity in the acute phase of anti-NMDAR encephalitis: a MEG study.
J Neurol. 2025;272:551.
PubMed Abstract available

MENASCU S, Drori T, Kalron A
Subcortical brain volume changes linked to concern of falling in multiple sclerosis: a structural MRI study.
J Neurol. 2025;272:552.
PubMed Abstract available

July 2025

DE SOUZA WAGNER PH, de Paiva FA, Mello JS, Silva ALM, et al
Clinical outcomes after switching from fingolimod to B-cell-depleting therapies in multiple sclerosis: systematic review and meta-analysis.
J Neurol. 2025;272:546.
PubMed Abstract available

HOU Y, Zhao B, Zheng J, Dai T, et al
Clinicopathological profiling and prognosis of idiopathic inflammatory myopathy overlapping with myasthenia gravis: a retrospective cohort study.
J Neurol. 2025;272:542.
PubMed Abstract available

DINI M, Tacchini M, Gamberini G, Boschetti A, et al
Learning as a digital hallmark of cognition in multiple sclerosis: lessons from a digital symbol digit modalities test.
J Neurol. 2025;272:536.
PubMed Abstract available

FUNG WH, Wessels MHJ, Coerver EME, de Beukelaar J, et al
Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS).
J Neurol. 2025;272:530.
PubMed Abstract available

PAUL F, Zappacosta S, Narduzzi S, Khellaf M, et al
Management and burden of disease in people with myelin oligodendrocyte glycoprotein antibody-associated disease: data from an international, cross-sectional survey.
J Neurol. 2025;272:529.
PubMed Abstract available

DAI Y, Yin Q, Han B, Yuan T, et al
MOG-IgG detection in serum and cerebrospinal fluid: diagnostic implications and clinical correlates in adult-onset Chinese MOGAD patients.
J Neurol. 2025;272:528.
PubMed Abstract available

WANG R, Wang X, Sun D, Shi Z, et al
Serum GFAP and NFL as biomarkers for disease activity, severity and disability in NMOSD.
J Neurol. 2025;272:521.
PubMed Abstract available

DONEDDU PE, Moretti G, Di Stefano V, Falzone Y, et al
Prevalence of hereditary transthyretin amyloidosis in CIDP patients with red flags: a multicenter genetic screening and misdiagnosis analysis.
J Neurol. 2025;272:515.
PubMed Abstract available

VITTURI BK, Cellerino M, Boccia D, Leray E, et al
Environmental risk factors for multiple sclerosis: a comprehensive systematic review and meta-analysis.
J Neurol. 2025;272:513.
PubMed Abstract available

RUBIN M, Cutillo G, Viti V, Margoni M, et al
MOGAD-related epilepsy: a systematic characterization of age-dependent clinical, fluid, imaging and neurophysiological features.
J Neurol. 2025;272:508.
PubMed Abstract available

COLEMAN A, Touze A, Farag M, Pengo M, et al
Evaluating finger-prick blood collection for remote quantification of neurofilament light in neurological diseases.
J Neurol. 2025;272:501.
PubMed Abstract available

HELLMANN MA, Steiner I, Mermelstein M, Friedman I, et al
Familial myasthenia gravis: characterization of an Israeli cohort and systematic review of the literature.
J Neurol. 2025;272:498.
PubMed Abstract available

NICOLELLA V, Varelli M, Fasano S, Sirica R, et al
Clinical application of age-derived cut-offs for plasma neurofilament light chain in multiple sclerosis.
J Neurol. 2025;272:495.
PubMed Abstract available

YAGIZ OZOGUL Y, Esatoglu SN, Ozogul M, Kizilkilic O, et al
Central nervous system involvement and mimickers in ANCA associated vasculitis.
J Neurol. 2025;272:492.
PubMed Abstract available

CAGOL A, Schaedelin S, Ocampo-Pineda M, Benkert P, et al
Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis Cohort.
J Neurol. 2025;272:491.
PubMed Abstract available

WANG Y, Nao J, Duan Y, Li Z, et al
Therapeutic strategies targeting complement in myasthenia gravis patients.
J Neurol. 2025;272:489.
PubMed Abstract available

VAN TILBURG SJ, Kocer S, Geissler J, van Rijs W, et al
Genetic variation of low-to-medium-affinity Fc-gamma receptors in Guillain-Barre syndrome.
J Neurol. 2025;272:487.
PubMed Abstract available

LIMA SM, Rini N, Cali A, Brighina F, et al
Clonidine for the management of crises in stiff-person syndrome.
J Neurol. 2025;272:485.
PubMed Abstract available

June 2025

ZACCONE T, Moiola L, Guerrieri S, Nozzolillo A, et al
Long-term effectiveness and safety of ocrelizumab: a single-centre real-world study.
J Neurol. 2025;272:481.
PubMed Abstract available

VERCELLINO M, Marasciulo S, Bosa C, Rolando A, et al
Added value of spinal cord MRI in detecting active disease in non-relapsing progressive multiple sclerosis patients.
J Neurol. 2025;272:482.
PubMed Abstract available

NAUTA IM, Loughlin KNM, Gravesteijn AS, van Wegen J, et al
A multi-domain lifestyle intervention in multiple sclerosis: a longitudinal observational study.
J Neurol. 2025;272:476.
PubMed Abstract available

VORASOOT N, Isitan-Alkawadri C, Pillai B, Miske R, et al
DAGLA autoantibody experience at Mayo Clinic.
J Neurol. 2025;272:460.
PubMed

HEWAMADDUMA C, Freimer M, Genge A, Leite MI, et al
Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis.
J Neurol. 2025;272:457.
PubMed Abstract available

BURGUET VILLENA F, Cerda-Fuertes N, Hofer L, Schadelin S, et al
Retinal neuronal loss and progression independent of relapse activity in multiple sclerosis.
J Neurol. 2025;272:454.
PubMed Abstract available

SAMADZADEH S, Chan F, Francis A, Sani L, et al
The impact of autoimmune comorbidities on the onset attack recovery in adults with AQP4-NMOSD and MOGAD.
J Neurol. 2025;272:453.
PubMed Abstract available

HERAUD C, Bresch S, Bourg V, Landes-Chateau C, et al
Monitoring anti-Rituximab antibodies in myasthenia gravis affects the time to event during Rituximab treatment.
J Neurol. 2025;272:451.
PubMed Abstract available

ZANETTA C, Gasperini C, Amato MP, Centonze D, et al
Potential use of the SARS-CoV-2 monoclonal antibody sipavibart in people with multiple sclerosis: definition of different patient archetypes from an Italian expert group perspective.
J Neurol. 2025;272:446.
PubMed Abstract available

CHEN H
A disproportionality analysis of nervous system adverse events associated with disease-modifying therapies in multiple sclerosis: insights from the FDA adverse event reporting system (FAERS).
J Neurol. 2025;272:445.
PubMed Abstract available

MALUCCHI S, Bava CI, Valentino P, Martire S, et al
Correction: In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12 months outcome: data from a real-life clinical setting.
J Neurol. 2025;272:444.
PubMed

GERAN R, Steiner OL, Krasivskaya E, Hannemann U, et al
Inverse relation between serum neurofilament light chain and cognitive function in chronic inflammatory demyelinating polyneuropathy.
J Neurol. 2025;272:439.
PubMed Abstract available

May 2025

MACCORA S, Vinciguerra C, Messina C, Bevilacqua L, et al
Double seronegative myasthenia gravis and mimics: a retrospective cross-sectional study by two tertiary centers in the Southern Italy.
J Neurol. 2025;272:433.
PubMed Abstract available

NEYAL N, Krey KJ, Morrison HA, Nathoo N, et al
From checkboxes to emojis: a novel approach to patient-reported outcomes in multiple sclerosis.
J Neurol. 2025;272:434.
PubMed Abstract available

GASPERINI C, Centonze D, Conte A, Gallo P, et al
Personalized therapy in multiple sclerosis: an Italian Delphi consensus.
J Neurol. 2025;272:428.
PubMed Abstract available

CLARELLI F, Corona A, Paakkonen K, Sorosina M, et al
Correction: Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study.
J Neurol. 2025;272:423.
PubMed

ARZALLUZ-LUQUE J, Dumez P, Picard G, Benaiteau M, et al
Clinical course and long-term outcomes in autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy.
J Neurol. 2025;272:421.
PubMed Abstract available

GIOFRE F, Lugaresi A, Baccari F, Lui E, et al
The topography of infratentorial lesions in depression and anxiety in multiple sclerosis.
J Neurol. 2025;272:420.
PubMed Abstract available

PIGNOLO A, Vinciguerra C, Monastero R, Rini N, et al
Rituximab in stiff-person syndrome with glutamic acid decarboxylase 65 autoantibody: a systematic review.
J Neurol. 2025;272:417.
PubMed Abstract available

DAVIES L, Shehadeh R, Watkins WJ, Jolles S, et al
Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis.
J Neurol. 2025;272:415.
PubMed Abstract available

CAO S, Zhou X, Du J, Zhang J, et al
Relapses during treatment with monoclonal antibodies targeting B-cells in NMOSD.
J Neurol. 2025;272:406.
PubMed Abstract available

ZHANG Y, Li G, Su H, Liang Y, et al
Effects of exercise on balance function in people with multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials.
J Neurol. 2025;272:405.
PubMed Abstract available

GERVASONI E, Torchio A, Bertoni R, Chieffo R, et al
Beyond EDSS: multidomain impairments are detectable and associated with walking disorders in low-disabled people with multiple sclerosis.
J Neurol. 2025;272:404.
PubMed Abstract available

WANG Z, Tan H, Huang W, Fan Y, et al
Fluctuations in serum aquaporin-4 antibody titers: the clinical significance in neuromyelitis optica spectrum disorder.
J Neurol. 2025;272:403.
PubMed Abstract available

FREEDMAN MS, Abdelhak A, Bhutani MK, Freeman J, et al
The role of serum neurofilament light (sNfL) as a biomarker in multiple sclerosis: insights from a systematic review.
J Neurol. 2025;272:400.
PubMed Abstract available

KIM YS, Shin IJ, Park DG, Yoon JH, et al
Hashimoto's encephalopathy with diffuse leukoencephalopathy: serial MRI and gait analysis.
J Neurol. 2025;272:399.
PubMed

ROSSINI E, Di Stefano V, Iorio R, Habetswallner F, et al
Ravulizumab for generalized Myasthenia Gravis: a multicenter real-life experience.
J Neurol. 2025;272:396.
PubMed Abstract available

TARANU D, Balz LT, Holbrook J, Tumani V, et al
Cognitive impairment, mood, and fatigue in various multiple sclerosis subtypes: a one-year follow-up study.
J Neurol. 2025;272:398.
PubMed Abstract available

ROCCA MA, Ratzinger S, Preziosa P, Meani A, et al
Clinical integration of brain and cord MRI features improves differential diagnosis of multiple sclerosis.
J Neurol. 2025;272:388.
PubMed Abstract available

HU S, Liao Z, Wang R, Zhang M, et al
Relapse risk after rituximab discontinuation in neuromyelitis optica spectrum disorders: a multi-center retrospective cohort study.
J Neurol. 2025;272:387.
PubMed Abstract available

FILIPPI M, Preziosa P, Rocca MA
Randomized controlled trials for multiple sclerosis: integrating pathology-driven outcomes to capture therapeutic efficacy.
J Neurol. 2025;272:385.
PubMed

ROY S, Huang Y, Hu C, Fitzgerald KC, et al
Core diagnostic features of stiff person syndrome: insights from a case-control study.
J Neurol. 2025;272:377.
PubMed Abstract available

FREEDMAN DE, Oh J, Einstein G, Feinstein A, et al
Aging and the neuropsychiatry of multiple sclerosis: a cross-sectional study.
J Neurol. 2025;272:375.
PubMed Abstract available

KOLB H, Shachaf Y, Fainberg K, Golan M, et al
Intrathecal methotrexate in progressive multiple sclerosis: a phase 1 open-label study with long-term follow-up.
J Neurol. 2025;272:374.
PubMed Abstract available

HERMAN D, Tanniou J, Leray E, Pierret C, et al
Analyzing recurrent events in multiple sclerosis: a review of statistical models with application to the MSOAC database.
J Neurol. 2025;272:371.
PubMed Abstract available

KUUTTI K, Laakso SM, Viitala M, Atula S, et al
Mortality and causes of death for people with multiple sclerosis: a Finnish nationwide register study.
J Neurol. 2025;272:370.
PubMed Abstract available

April 2025

CACCIAGUERRA L, Madhavan A, Sechi E, Krecke KN, et al
Utility of spinal cord axial-T2 sequence in a population-based cohort of multiple sclerosis.
J Neurol. 2025;272:367.
PubMed

PANE C, Di Stefano V, Cuomo N, Sarnataro A, et al
Correction: A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients.
J Neurol. 2025;272:366.
PubMed

SEERY N, Wesselingh R, Beech P, Broadley J, et al
Multimodal prognostication of autoimmune encephalitis: an Australian autoimmune encephalitis consortium study.
J Neurol. 2025;272:361.
PubMed Abstract available

MAHMOUDI N, Renne J, Konen FF, Jendretzky KF, et al
Added value of optic nerve lesions for multiple sclerosis diagnostic criteria.
J Neurol. 2025;272:358.
PubMed Abstract available

CAMPETELLA L, Smolik K, Farina A, Joubert B, et al
Neurodegeneration and the immune system: lessons from autoimmune encephalitis.
J Neurol. 2025;272:359.
PubMed Abstract available

SIRIRATNAM P, Huda S, Van der Walt A, Sanfilippo P, et al
Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD: an international cohort study.
J Neurol. 2025;272:339.
PubMed Abstract available

LEAVITT V, Mostert J, Comtois J, Moral E, et al
Measuring cognitive change in secondary progressive MS: an analysis of the ASCEND cognition substudy.
J Neurol. 2025;272:338.
PubMed Abstract available

BALSHI A, Dempsey J, Kumbar S, Leuenberger G, et al
Correction: Marriage is associated with decreased lesion volumes and less brain atrophy in people with multiple sclerosis.
J Neurol. 2025;272:337.
PubMed

OJHA A, Tommasin S, Piervincenzi C, Baione V, et al
Clinical and MRI features contributing to the clinico-radiological dissociation in a large cohort of people with multiple sclerosis.
J Neurol. 2025;272:327.
PubMed Abstract available

HONG J, Gaubert M, Lefort M, Ferre JC, et al
Limited added value of systematic spinal cord MRI vs brain MRI alone to classify patients with MS as active or inactive during follow-up.
J Neurol. 2025;272:316.
PubMed Abstract available

MOIOLA L, Mandelli A, Tarkowski M, Finardi A, et al
Recall vaccination increases detectable B-cell reactivity in persons with multiple sclerosis treated with ocrelizumab.
J Neurol. 2025;272:314.
PubMed Abstract available

LADOPOULOS T, Abbas Z, Krieger B, Bellenberg B, et al
Neurological disability and brain grey matter atrophy in primary progressive multiple sclerosis are determined by microstructural lesional changes, but not by lesion load.
J Neurol. 2025;272:302.
PubMed Abstract available

March 2025

KONITSIOTI AM, Laurent S, Ellenberger D, Stahmann A, et al
MS treatment trends before, during, and after the COVID-19 pandemic: insights from the German MS Register.
J Neurol. 2025;272:294.
PubMed Abstract available

KHERBEK H, Paramasivan NK, Dasari S, Karsten C, et al
Exploring autoantigens in autoimmune limbic encephalitis using phage immunoprecipitation sequencing.
J Neurol. 2025;272:292.
PubMed Abstract available

RITTEL JC, Hudasch D, Doppler K, Bergh FT, et al
Intravenous immunoglobulin as first-line acute treatment in adults with autoimmune encephalitis caused by antibodies to NMDAR, LGI1 and CASPR2.
J Neurol. 2025;272:287.
PubMed Abstract available

LADEIRA F, Nobrega C, Cerqueira J
Evaluation of the efficacy of the SARS-CoV-2 vaccine additional and booster doses in immunocompromised patients with multiple sclerosis: the COVACiMS study.
J Neurol. 2025;272:288.
PubMed Abstract available

FUJII S, Yaguchi H, Kudo A, Eguchi K, et al
Autoimmune cerebellar ataxia with Kelch-like protein 11 antibodies in a large cohort study.
J Neurol. 2025;272:282.
PubMed

FARINA A, Villagran-Garcia M, Abichou-Klich A, Benaiteau M, et al
Application of the anti-IgLON5 disease composite score to assess severity, clinical course, and mortality in a French cohort.
J Neurol. 2025;272:273.
PubMed Abstract available

BRIL V, Druzdz A, Grosskreutz J, Habib AA, et al
Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open-label extension MG0004 study.
J Neurol. 2025;272:275.
PubMed Abstract available

DING Y, Wu D, Chu H, Tang Y, et al
Clinical characterization of diseases associated with anti-N-methyl-D-aspartate receptor encephalitis combined with anti-myelin oligodendrocyte glycoprotein antibodies in adults.
J Neurol. 2025;272:262.
PubMed Abstract available

SORENSEN NV, Nilsson AC, Dos AH, Stenor CM, et al
Anti-GFAP associated opsoclonus-myoclonus-ataxia syndrome in a patient with multiple autoimmune comorbidities-a case report.
J Neurol. 2025;272:263.
PubMed

KOMATSU T, Motegi H, Mimori M, Okumura M, et al
Predictors of achieving minimal manifestations or better status in ocular myasthenia gravis with immunotherapy.
J Neurol. 2025;272:243.
PubMed Abstract available

BOSTAN M, Li C, Cheong JW, Wong DWK, et al
Longitudinal analysis of retinal and choriocapillaris in patients with multiple sclerosis: a 3-year study.
J Neurol. 2025;272:237.
PubMed Abstract available

February 2025

AZZIMONTI M, Preziosa P, Pagani E, Meani A, et al
Cervical spinal cord gray matter damage predicts disability worsening in multiple sclerosis: a longitudinal study.
J Neurol. 2025;272:228.
PubMed Abstract available

PARAMASIVAN NK, Sarker P, Zekeridou A, Staff NP, et al
Upper motor neuron-predominant motor neuron disease: a novel immunotherapy-responsive association of GAD65 autoimmunity.
J Neurol. 2025;272:230.
PubMed Abstract available

BINKS SNM, Morse IM, Ashraghi M, Vincent A, et al
Myasthenia gravis in 2025: five new things and four hopes for the future.
J Neurol. 2025;272:226.
PubMed Abstract available

SCHONHERR C, Ziegler J, Zentek T, Rashid A, et al
Smartphone-based gait analysis in the assessment of fatigue and fatigability in people with multiple sclerosis: a supervised cohort study.
J Neurol. 2025;272:217.
PubMed Abstract available

BALSHI A, Dempsey J, Manning N, Leuenberger G, et al
A disproportionality analysis of surgical site infections across multiple sclerosis disease modifying therapies.
J Neurol. 2025;272:223.
PubMed Abstract available

NAYAK S, Wagshul ME, Foley FW, Motl RW, et al
Associations between connectivity in functional brain networks and gait speed in older adults with and without multiple sclerosis.
J Neurol. 2025;272:216.
PubMed Abstract available

DI SABATINO E, Ferraro D, Gaetani L, Emiliano E, et al
CSF biomarkers of B-cell activation in multiple sclerosis: a clinical perspective.
J Neurol. 2025;272:211.
PubMed Abstract available

MARASTONI D, Sicchieri M, Pizzini FB, Scartezzini A, et al
Multiple sclerosis diagnosis and its differential diagnosis in patients presenting with type four 'mirror pattern' CSF oligoclonal bands.
J Neurol. 2025;272:207.
PubMed Abstract available

NISHIMORI Y, Tanboon J, Oyama M, Motegi H, et al
Anti-mitochondrial M2 antibody-positive myositis may be an independent subtype of autoimmune myositis.
J Neurol. 2025;272:206.
PubMed Abstract available

CHEN X, Wang R, Li R, Hu S, et al
A real-world study on the utility of regular rituximab treatment for neuromyelitis optica spectrum disorder.
J Neurol. 2025;272:194.
PubMed Abstract available

FILIPPI M, Amato MP, Avolio C, Gallo P, et al
Towards a biological view of multiple sclerosis from early subtle to clinical progression: an expert opinion.
J Neurol. 2025;272:179.
PubMed Abstract available

HANSEL M, Reichmann H, Haehner A, Schmitz-Peiffer H, et al
Hippocampal dysfunction after autoimmune encephalitis depending on the antibody type.
J Neurol. 2025;272:175.
PubMed Abstract available

January 2025

GIANNOPAPAS V, Smyrni V, Kitsos DK, Stefanou MI, et al
Cancer in multiple sclerosis patients following prolonged exposure to disease-modifying therapies (DMTs): a systematic review and meta-analysis.
J Neurol. 2025;272:162.
PubMed Abstract available

DE ARMAS FERNANDEZ JR, Garcia CEP, Herrera BA, Garcia FD, et al
Incidence of Guillain-Barre syndrome in Cuba before and during the Oropouche virus emergency, 2018-2024.
J Neurol. 2025;272:164.
PubMed

BOAVENTURA M, Fragoso DC, Avolio I, Pereira SA, et al
Brain tissue integrity in neuromyelitis optica spectrum disorder through T1-w/T2-w ratio, MTR and DTI.
J Neurol. 2025;272:157.
PubMed Abstract available

INOJOSA H, Schriefer D, Ness NH, Dillenseger A, et al
Cost-consequence analysis of early vs. delayed natalizumab use in highly active relapsing-remitting multiple sclerosis: a simulation study.
J Neurol. 2025;272:153.
PubMed Abstract available

PIHL-JENSEN G, Frederiksen JL
The value of magnetic resonance imaging of the optic nerve for the diagnosis of multiple sclerosis in patients with optic neuritis.
J Neurol. 2025;272:131.
PubMed Abstract available

LAGEMAN SB, Jolly A, Sahi N, Prados F, et al
Explaining cognitive function in multiple sclerosis through networks of grey and white matter features: a joint independent component analysis.
J Neurol. 2025;272:142.
PubMed Abstract available

MIRMOSAYYEB O, Weinstock-Guttman B, Zivadinov R, Jakimovski D, et al
Anatomy-driven segmentation of parafoveal optical coherence tomography (OCT) measures may improve associations with clinical outcomes in multiple sclerosis.
J Neurol. 2025;272:141.
PubMed Abstract available

BALSHI A, Dempsey J, Kumbar S, Leunberger G, et al
Marriage is associated with decreased lesion volumes and less brain atrophy in people with multiple sclerosis.
J Neurol. 2025;272:151.
PubMed Abstract available

MAR S, Valeriani M, Steinborn B, Schreiner T, et al
Ocrelizumab dose selection for treatment of pediatric relapsing-remitting multiple sclerosis: results of the OPERETTA I study.
J Neurol. 2025;272:137.
PubMed Abstract available

MAIWORM M, Koerbel K, Anschutz V, Jakob J, et al
BDNF levels in serum and CSF are associated with clinicoradiological characteristics of aggressive disease in MS patients.
J Neurol. 2025;272:147.
PubMed Abstract available

PREZIOSA P, Pagani E, Meani A, Margoni M, et al
Soma and neurite density abnormalities of paramagnetic rim lesions and core-sign lesions in multiple sclerosis.
J Neurol. 2025;272:145.
PubMed Abstract available

PLESS S, Woelfle T, Lorscheider J, Wiencierz A, et al
CoGames: Development of an adaptive smartphone-based and gamified monitoring tool for cognitive function in Multiple Sclerosis.
J Neurol. 2025;272:119.
PubMed Abstract available

ZANGHI A, Greco A, Giancipoli E, Tumani H, et al
Unraveling the inflammation-degeneration tangle in early MS: preliminary insights from ferritin, neurogranin, TREM2, and retinal ganglion cell layer.
J Neurol. 2025;272:109.
PubMed Abstract available

FOCKE JK, Brokbals M, Becker J, Veltkamp R, et al
Cerebral vasculitis related to neurosarcoidosis: a case series and systematic literature review.
J Neurol. 2025;272:135.
PubMed Abstract available

LIU M, Ren H, Yao D, Yao M, et al
Autoimmune cerebellar ataxia associated with anti-SEZ6L2 antibody: report of three cases.
J Neurol. 2025;272:127.
PubMed

ROBERTSON NP
Bruton's tyrosine kinase inhibitor for multiple sclerosis: new hope or false dawn.
J Neurol. 2025;272:106.
PubMed Abstract available

FAROOQI AM, Sawalha A, Omidi SJ, Dubey D, et al
Seizures and status epilepticus in anti-NMDA receptor encephalitis.
J Neurol. 2025;272:95.
PubMed Abstract available

WALBAUM M, Madhukar A, Dobson R, Cyhlarova E, et al
Cost effectiveness of different treatment strategies with natalizumab for pregnant women with multiple sclerosis.
J Neurol. 2025;272:93.
PubMed Abstract available

FILIPPI M, Gallo P, Gasperini C, Marfia GA, et al
Implementing proximity care for people with multiple sclerosis in Italy: the bottom-up approach of the StayHome project.
J Neurol. 2025;272:96.
PubMed Abstract available

SCHUMACHER A, Hieke A, Spenner M, Schmitz F, et al
Early therapy initiation is crucial in chronic inflammatory demyelinating polyneuropathy: prospective multimodal data from the German INHIBIT registry.
J Neurol. 2025;272:100.
PubMed Abstract available

December 2024

NICOLESCU M, Haussler V, Paul F, Oertel FC, et al
Visual quality of life in NMOSD and MOGAD: profiles, dynamics and associations with ageing and vision.
J Neurol. 2024;272:86.
PubMed Abstract available

BARBA L, Gaetani L, Sperandei S, Di Sabatino E, et al
CSF synaptic biomarkers and cognitive impairment in multiple sclerosis.
J Neurol. 2024;272:85.
PubMed Abstract available

MIRMOSAYYEB O, Yazdan Panah M, Moases Ghaffary E, Vaheb S, et al
Magnetic resonance imaging-based biomarkers of multiple sclerosis and neuromyelitis optica spectrum disorder: a systematic review and meta-analysis.
J Neurol. 2024;272:77.
PubMed Abstract available

INAN B, Ozturk B, Ata N, Ulgu MM, et al
A nationwide epidemiological study of myasthenia gravis in Turkey.
J Neurol. 2024;272:5.
PubMed Abstract available

VECCHIO D, Puricelli C, Virgilio E, Passarelli F, et al
Kappa index for multiple sclerosis diagnosis: an accurate biomarker of intrathecal synthesis.
J Neurol. 2024;272:30.
PubMed Abstract available

PONZIO M, Santoni L, Molina M, Tavazzi E, et al
Economic burden of multiple sclerosis in an Italian cohort of patients on disease-modifying therapy: analysis of disease cost and its components.
J Neurol. 2024;272:50.
PubMed Abstract available

DE BLASIIS P, Massimiani A, Inglese C, Bianchini E, et al
Spasticity patterns assessment and recognition for therapeutic approaches (SPARTA) in multiple sclerosis: a multicenter epidemiological study.
J Neurol. 2024;272:34.
PubMed Abstract available

KLIMAS R, Sturm D, Altenborg A, Stylianou N, et al
Assessing axonal pathology and disease progression in chronic inflammatory demyelinating polyneuropathy using corneal confocal microscopy.
J Neurol. 2024;272:51.
PubMed Abstract available

BUGGE C, Engebretsen I, Kristiansen IS, Saether EM, et al
Medical costs of treating myasthenia gravis in patients who need intravenous immunoglobulin (IVIg) - a register-based study.
J Neurol. 2024;272:15.
PubMed Abstract available

FASANO C, Bettiol A, Vastola M, Lotti A, et al
Effectiveness and safety of intravenous immunoglobulin for peripheral neuropathy in EGPA patients: a retrospective study.
J Neurol. 2024;272:13.
PubMed Abstract available

GASPERINI C, Battaglia MA, Balzani F, Chiarini E, et al
Unveiling preferences in multiple sclerosis care: insights from an Italian discrete-choice experiment with patients and healthcare professionals.
J Neurol. 2024;272:27.
PubMed Abstract available

COMABELLA M, Hegen H, Villar LM, Rejdak K, et al
Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis.
J Neurol. 2024;272:26.
PubMed Abstract available

MARLET IR, Andersen RK, Axelsen KH, Andersen LK, et al
Factors affecting the diagnostic delay of myasthenia gravis.
J Neurol. 2024;272:29.
PubMed Abstract available

FILIPPI M, Margoni M, Zaccone T, Guerrieri S, et al
Disability worsening outcome in multiple sclerosis based on EDSS: does half a point matter?
J Neurol. 2024;272:9.
PubMed

November 2024

PAKEERATHAN T, Havla J, Schwake C, Salmen A, et al
Rapid differentiation of MOGAD and MS after a single optic neuritis.
J Neurol. 2024;271:7222-7231.
PubMed Abstract available

October 2024

FACCIORUSSO S, Malfitano C, Giordano M, Del Furia MJ, et al
Effectiveness of robotic rehabilitation for gait and balance in people with multiple sclerosis: a systematic review.
J Neurol. 2024 Oct 10. doi: 10.1007/s00415-024-12715.
PubMed Abstract available

TARD C, Laforet P, de Pouvourville G, Crochard A, et al
Treatment of myasthenia gravis in france: A retrospective claims database study (STAMINA).
J Neurol. 2024 Oct 10. doi: 10.1007/s00415-024-12714.
PubMed Abstract available

MOSER T, Gruber J, Mylonaki E, Bohm V, et al
Autoimmune and infectious encephalitis: development of a discriminative tool for early diagnosis and initiation of therapy.
J Neurol. 2024 Oct 5. doi: 10.1007/s00415-024-12712.
PubMed Abstract available

BALCK A, Lange LM, Neumann A, Royl G, et al
Highly beneficial outcome in severe acute necrotizing encephalopathy with tocilizumab treatment.
J Neurol. 2024;271:7042-7045.
PubMed

SELMAJ K, Hartung HP, Mycko MP, Selmaj I, et al
MS treatment de-escalation: review and commentary.
J Neurol. 2024;271:6426-6438.
PubMed Abstract available

September 2024

MALUCCHI S, Bava CI, Valentino P, Martire S, et al
In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12 months outcome: data from a real-life clinical setting.
J Neurol. 2024 Sep 23. doi: 10.1007/s00415-024-12701.
PubMed Abstract available

PEKMEZOVIC T, Jovicevic V, Andabaka M, Momcilovic N, et al
Aquaporin4-IgG seropositivity significantly increases the risk of comorbid autoimmune diseases in NMOSD patients: population-based registry data.
J Neurol. 2024 Sep 22. doi: 10.1007/s00415-024-12698.
PubMed Abstract available

MARGONI M, Valsasina P, Moiola L, Mistri D, et al
Monoaminergic network abnormalities are associated with fatigue in pediatric multiple sclerosis.
J Neurol. 2024 Sep 19. doi: 10.1007/s00415-024-12689.
PubMed Abstract available

MENG H, He L, Chunyu H, Zhou Q, et al
(18)F-DPA714 PET/MRI as a potential imaging tool for detecting possible antibody-negative autoimmune encephalitis: a prospective study.
J Neurol. 2024 Sep 19. doi: 10.1007/s00415-024-12690.
PubMed Abstract available

MANGIORIS G, Orozco E, Dubey D, Flanagan EP, et al
Long-term outcomes in antibody-negative autoimmune encephalitis: a retrospective study.
J Neurol. 2024 Sep 15. doi: 10.1007/s00415-024-12680.
PubMed Abstract available

KONITSIOTI AM, Pruss H, Laurent S, Fink GR, et al
Chimeric antigen receptor T-cell therapy for autoimmune diseases of the central nervous system: a systematic literature review.
J Neurol. 2024 Sep 14. doi: 10.1007/s00415-024-12642.
PubMed Abstract available

YOUSEF H, Malagurski Tortei B, Castiglione F
Predicting multiple sclerosis disease progression and outcomes with machine learning and MRI-based biomarkers: a review.
J Neurol. 2024 Sep 12. doi: 10.1007/s00415-024-12651.
PubMed Abstract available

CLARELLI F, Corona A, Paakkonen K, Sorosina M, et al
Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study.
J Neurol. 2024 Sep 12. doi: 10.1007/s00415-024-12608.
PubMed Abstract available

HAFSTEINSDOTTIR B, Farman H, Lagerstrom N, Zetterberg H, et al
Neurofilament light chain as a diagnostic and prognostic biomarker in Guillain-Barre syndrome.
J Neurol. 2024 Sep 9. doi: 10.1007/s00415-024-12679.
PubMed Abstract available

CALLEN AM, Zurawski J, Chu R, Tie Y, et al
The role of 7 T MRI to assess atrophy of the subcortical deep gray matter in relapsing-remitting multiple sclerosis.
J Neurol. 2024 Sep 6. doi: 10.1007/s00415-024-12656.
PubMed Abstract available

DELUCA J
Correction to: Fatigue in multiple sclerosis: can we measure it and can we treat it?
J Neurol. 2024 Sep 6. doi: 10.1007/s00415-024-12630.
PubMed

PORTACCIO E, Betti M, De Meo E, Addazio I, et al
Correction to: Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression.
J Neurol. 2024 Sep 4. doi: 10.1007/s00415-024-12627.
PubMed

GIOSSI R, Mercenari M, Filippi M, Zanetta C, et al
Correction to: Unprescribed cannabinoids and multiple sclerosis: a multicenter, cross-sectional, epidemiological study in Lombardy, Italy.
J Neurol. 2024 Sep 3. doi: 10.1007/s00415-024-12560.
PubMed

SHI Z, Kong L, Wang R, Wang X, et al
Cytomegalovirus and Epstein-Barr virus infections in patients with neuromyelitis optica spectrum disorder.
J Neurol. 2024;271:6089-6095.
PubMed Abstract available

QUINT P, Schroeter CB, Kohle F, Ozturk M, et al
Preventing long-term disability in CIDP: the role of timely diagnosis and treatment monitoring in a multicenter CIDP cohort.
J Neurol. 2024;271:5930-5943.
PubMed Abstract available

HECHLER A, Kuchling J, Muller-Jensen L, Klag J, et al
Hippocampal hub failure is linked to long-term memory impairment in anti-NMDA-receptor encephalitis: insights from structural connectome graph theoretical network analysis.
J Neurol. 2024;271:5886-5898.
PubMed Abstract available

ABBOUD H, Sun R, Modak N, Elkasaby M, et al
Spinal movement disorders in NMOSD, MOGAD, and idiopathic transverse myelitis: a prospective observational study.
J Neurol. 2024;271:5875-5885.
PubMed Abstract available

August 2024

WURDACK K, Pruss H, Finke C
Evolution from viral encephalitis to autoimmune encephalitis to multiple sclerosis: a case report.
J Neurol. 2024 Aug 31. doi: 10.1007/s00415-024-12659.
PubMed Abstract available

CHISARI CG, Amato MP, Di Sapio A, Foschi M, et al
Active and non-active secondary progressive multiple sclerosis patients exhibit similar disability progression: results of an Italian MS registry study (ASPERA).
J Neurol. 2024 Aug 27. doi: 10.1007/s00415-024-12621.
PubMed Abstract available

BAYAT M, Harbo T, Anzabi M, Bayat A, et al
POLG-related mitochondrial disease mimicking autoimmune encephalitis.
J Neurol. 2024 Aug 24. doi: 10.1007/s00415-024-12641.
PubMed

CAROTENUTO A, Di Monaco C, Papetti L, Borriello G, et al
Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod.
J Neurol. 2024 Aug 23. doi: 10.1007/s00415-024-12610.
PubMed Abstract available

SIMONE M, Lucisano G, Guerra T, Paolicelli D, et al
Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis.
J Neurol. 2024 Aug 23. doi: 10.1007/s00415-024-12638.
PubMed Abstract available

MISCIOSCIA A, Mainero C, Treaba CA, Silvestri E, et al
The contribution of paramagnetic rim and cortical lesions to physical and cognitive disability at multiple sclerosis clinical onset: evaluating the power of MRI and OCT biomarkers.
J Neurol. 2024 Aug 19. doi: 10.1007/s00415-024-12622.
PubMed Abstract available

DUMEZ P, Villagran-Garcia M, Bani-Sadr A, Benaiteau M, et al
Specific clinical and radiological characteristics of anti-NMDA receptor autoimmune encephalitis following herpes encephalitis.
J Neurol. 2024 Aug 16. doi: 10.1007/s00415-024-12615.
PubMed Abstract available

KOKUBUN N, Tsuchiya T, Hamaguchi M, Ueda Y, et al
IgG subclass shifts occurring at acute exacerbations in autoimmune nodopathies.
J Neurol. 2024 Aug 2. doi: 10.1007/s00415-024-12597.
PubMed Abstract available

ARNETT S, Chew SH, Leitner U, Hor JY, et al
Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis.
J Neurol. 2024;271:4794-4812.
PubMed Abstract available

ARNETT SV, Prain K, Ramanathan S, Bhuta S, et al
Long-term outcomes of ADEM-like and tumefactive presentations of CNS demyelination: a case-comparison analysis.
J Neurol. 2024;271:5275-5289.
PubMed Abstract available

KLIMAS R, Kordes A, Huckemann S, Gasz Z, et al
The multiple roles of nerve biopsy in the diagnosis and prognosis of suspected immune neuropathies.
J Neurol. 2024;271:5109-5121.
PubMed Abstract available

RECHTMAN A, Freidman-Korn T, Zveik O, Shweiki L, et al
Assessing the applicability of the 2023 international MOGAD panel criteria in real-world clinical settings.
J Neurol. 2024;271:5102-5108.
PubMed Abstract available

ZHANG L, Zhang Y, Li R, Zhu J, et al
Anti-neurofascin-155 antibody mediated a distinct phenotype of chronic inflammatory demyelinating polyradiculoneuropathy.
J Neurol. 2024;271:4991-5002.
PubMed Abstract available

COLY M, Adams D, Attarian S, Bouhour F, et al
Clinical, paraclinical and outcome features of 166 patients with acute anti-GQ1b antibody syndrome.
J Neurol. 2024;271:4982-4990.
PubMed Abstract available

ZIVADINOV R, Jakimovski D, Burnham A, Kuhle J, et al
Neuroimaging assessment of facility-bound severely-affected MS reveals the critical role of cortical gray matter pathology: results from the CASA-MS case-controlled study.
J Neurol. 2024;271:4949-4962.
PubMed Abstract available

July 2024

PANE C, Di Stefano V, Cuomo N, Sarnataro A, et al
A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients.
J Neurol. 2024 Jul 30. doi: 10.1007/s00415-024-12588.
PubMed Abstract available

PAPATHANASIOU A, Tench CR, Ambrose PA, Sedehizadeh S, et al
Pre-thymectomy disease severity predicts outcome in acetylcholine receptor antibody-positive generalised myasthenia gravis.
J Neurol. 2024 Jul 30. doi: 10.1007/s00415-024-12592.
PubMed Abstract available

FILIPPI M, Pagani E, Turrini R, Bartezaghi M, et al
Effects of fingolimod on focal and diffuse damage in patients with relapsing-remitting multiple sclerosis - The "EVOLUTION" study.
J Neurol. 2024 Jul 29. doi: 10.1007/s00415-024-12590.
PubMed Abstract available

MANZANO GS, Levy M, Salky R, Mateen FJ, et al
Assessment of international MOGAD diagnostic criteria in patients with overlapping MOG-associated disease and multiple sclerosis phenotypes.
J Neurol. 2024 Jul 27. doi: 10.1007/s00415-024-12585.
PubMed Abstract available

MITOMA H, Manto M
Recent advances in diagnosis of immune-mediated cerebellar ataxias: novel concepts and fundamental questions on autoimmune mechanisms.
J Neurol. 2024 Jul 25. doi: 10.1007/s00415-024-12596.
PubMed Abstract available

PASSALI M, Galea I, Knudsen MH, Lau LC, et al
Cerebrospinal fluid neurofilament light chain in acute optic neuritis and its predictive ability of multiple sclerosis.
J Neurol. 2024 Jul 25. doi: 10.1007/s00415-024-12587.
PubMed Abstract available

HABIB AA, Klink AJ, Muppidi S, Parthan A, et al
United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use.
J Neurol. 2024 Jul 25. doi: 10.1007/s00415-024-12569.
PubMed Abstract available

KARL AS, Klimas R, Katsimpoura M, Sgodzai M, et al
Quality of life and tolerability of B-cell directed therapy of multiple sclerosis with ofatumumab in a patient-centered real-world observational study.
J Neurol. 2024 Jul 22. doi: 10.1007/s00415-024-12581.
PubMed Abstract available

MOLENAAR PCG, Noteboom S, van Nederpelt DR, Krijnen EA, et al
Digital outcome measures are associated with brain atrophy in patients with multiple sclerosis.
J Neurol. 2024 Jul 15. doi: 10.1007/s00415-024-12516.
PubMed Abstract available

RAVANO V, Andelova M, Piredda GF, Sommer S, et al
Microstructural characterization of multiple sclerosis lesion phenotypes using multiparametric longitudinal analysis.
J Neurol. 2024 Jul 13. doi: 10.1007/s00415-024-12568.
PubMed Abstract available

VITI V, Zanetta C, Capra R, Municchi A, et al
Ocrelizumab-associated enteritis in patients with multiple sclerosis: an emerging safety issue.
J Neurol. 2024 Jul 11. doi: 10.1007/s00415-024-12553.
PubMed

ZHU F, Wang WF, Ma CH, Liang H, et al
Resolution of anti-LGI1-associated autoimmune encephalitis in a patient after treatment with efgartigimod.
J Neurol. 2024 Jul 9. doi: 10.1007/s00415-024-12556.
PubMed Abstract available

DELUCA J
Fatigue in multiple sclerosis: can we measure it and can we treat it?
J Neurol. 2024 Jul 5. doi: 10.1007/s00415-024-12524.
PubMed Abstract available

ROT U, Jerala M, Horvat Ledinek A, Brecl Jakob G, et al
Progressive multifocal leukoencephalopathy in association with siponimod treatment for secondary progressive multiple sclerosis: a case report.
J Neurol. 2024 Jul 3. doi: 10.1007/s00415-024-12542.
PubMed

PREZIOSA P, Amato MP, Battistini L, Capobianco M, et al
Moving towards a new era for the treatment of neuromyelitis optica spectrum disorders.
J Neurol. 2024;271:3879-3896.
PubMed Abstract available

KAPPOS L, Edan G, Freedman MS, Hartung HP, et al
Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial.
J Neurol. 2024;271:4599-4609.
PubMed Abstract available

ZANGHI A, Borriello G, Bonavita S, Fantozzi R, et al
Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study.
J Neurol. 2024;271:4495-4502.
PubMed Abstract available

WANG R, Sun D, Wang X, Shi Z, et al
Correlation between severe attacks and serum aquaporin-4 antibody titer in neuromyelitis optica spectrum disorder.
J Neurol. 2024;271:4503-4512.
PubMed Abstract available

HARTUNG HP, Berger T, Bermel RA, Brochet B, et al
ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial.
J Neurol. 2024;271:4348-4360.
PubMed Abstract available

PESTCHANKER C, Bertado Cortez B, Lana Peixoto MA, Gortari JI, et al
Occurrence of area postrema syndrome during follow-up: phenotype and influence over NMOSD activity in LATAM in real-world settings.
J Neurol. 2024;271:4292-4299.
PubMed Abstract available

MAKHANI N, Lebrun-Frenay C, Siva A, Shabanova V, et al
The diagnostic workup of children with the radiologically isolated syndrome differs by age and by sex.
J Neurol. 2024;271:4019-4027.
PubMed Abstract available

June 2024

LAL AP, Foong YC, Sanfilippo PG, Spelman T, et al
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic.
J Neurol. 2024 Jun 27. doi: 10.1007/s00415-024-12518.
PubMed Abstract available

GRIFFITH SP, Wesselingh R, Seery N, Rushen T, et al
Memory function in autoimmune encephalitis: a cross-sectional prospective study utilising multiple memory paradigms.
J Neurol. 2024 Jun 25. doi: 10.1007/s00415-024-12520.
PubMed Abstract available

NOTEBOOM S, Seiler M, Chien C, Rane RP, et al
Evaluation of machine learning-based classification of clinical impairment and prediction of clinical worsening in multiple sclerosis.
J Neurol. 2024 Jun 23. doi: 10.1007/s00415-024-12507.
PubMed Abstract available

SIMANI L, Molaeipour L, Kian S, Leavitt VM, et al
Correlation between cognitive changes and neuroradiological changes over time in multiple sclerosis: a systematic review and meta-analysis.
J Neurol. 2024 Jun 18. doi: 10.1007/s00415-024-12517.
PubMed Abstract available

FUNKE M, Eveslage M, Zschuntzsch J, Hagenacker T, et al
Fatigue and associated factors in myasthenia gravis: a nationwide registry study.
J Neurol. 2024 Jun 13. doi: 10.1007/s00415-024-12490.
PubMed Abstract available

YU H, Wang X, Pan Y, Li H, et al
Myasthenia gravis due to anti-PD-1 treatment for an advanced colon cancer patient: a case report and literature review.
J Neurol. 2024 Jun 12. doi: 10.1007/s00415-024-12494.
PubMed Abstract available

KONG X, Guo K, Liu X, Gong X, et al
Differentiation between viral and autoimmune limbic encephalitis: a prospective cohort study with development and validation of a diagnostic model.
J Neurol. 2024 Jun 11. doi: 10.1007/s00415-024-12468.
PubMed Abstract available

GIOSSI R, Mercenari M, Filippi M, Zanetta C, et al
Unprescribed cannabinoids and multiple sclerosis: a multicenter, cross-sectional, epidemiological study in Lombardy, Italy.
J Neurol. 2024 Jun 7. doi: 10.1007/s00415-024-12472.
PubMed Abstract available

MUCK A, Pfeuffer S, Mir L, Genau S, et al
Myasthenic crises are associated with negative long-term outcomes in myasthenia gravis.
J Neurol. 2024 Jun 5. doi: 10.1007/s00415-024-12478.
PubMed

HERAUD C, Bresch S, Landes-Chateau C, Bourg V, et al
Rituximab alone is as effective as associated with steroids on naive patients with generalized myasthenia gravis.
J Neurol. 2024 Jun 5. doi: 10.1007/s00415-024-12454.
PubMed Abstract available

STARK AJ, Mobley BC, Eaton JE
Progressive leukoencephalopathy as a manifestation of primary angiitis of the central nervous system: case report and review of the literature.
J Neurol. 2024;271:3648-3652.
PubMed Abstract available

May 2024

PORTACCIO E, Betti M, De Meo E, Addazio I, et al
Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression.
J Neurol. 2024 May 28. doi: 10.1007/s00415-024-12448.
PubMed Abstract available

HUANG W, Zhang H, Li X, Zhang J, et al
Prognostic factors underlying the development of drug-resistant epilepsy in patients with autoimmune encephalitis: a retrospective cohort study.
J Neurol. 2024 May 27. doi: 10.1007/s00415-024-12432.
PubMed Abstract available

CHAE J, Nguyen TT, Oh SY
Quantification of saccadic fatigability and diagnostic efficacy for myasthenia gravis.
J Neurol. 2024 May 26. doi: 10.1007/s00415-024-12461.
PubMed Abstract available

MONTEIRO I, Nicolella V, Fiorenza M, Novarella F, et al
The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis.
J Neurol. 2024 May 23. doi: 10.1007/s00415-024-12434.
PubMed Abstract available

FJORDSIDE L, Nissen MS, Florescu AM, Storgaard M, et al
Validation of a risk score to differentiate autoimmune and viral encephalitis: a Nationwide Cohort Study in Denmark.
J Neurol. 2024 May 18. doi: 10.1007/s00415-024-12392.
PubMed Abstract available

CORTESE R, Battaglini M, Stromillo ML, Luchetti L, et al
Regional hippocampal atrophy reflects memory impairment in patients with early relapsing remitting multiple sclerosis.
J Neurol. 2024 May 14. doi: 10.1007/s00415-024-12290.
PubMed Abstract available

WOLF E, Wicklein R, Aly L, Schmaderer C, et al
Optical coherence tomography angiography suggests different retinal pathologies in multiple sclerosis and Sjogren's syndrome.
J Neurol. 2024 May 14. doi: 10.1007/s00415-024-12414.
PubMed Abstract available

FREEDMAN DE, Oh J, Kiss A, Puopolo J, et al
The influence of depression and anxiety on cognition in people with multiple sclerosis: a cross-sectional analysis.
J Neurol. 2024 May 11. doi: 10.1007/s00415-024-12409.
PubMed Abstract available

BARDEL B, Creange A, Bonardet N, Bapst B, et al
Motor function in multiple sclerosis assessed by navigated transcranial magnetic stimulation mapping.
J Neurol. 2024 May 6. doi: 10.1007/s00415-024-12398.
PubMed Abstract available

GALPERIN I, Buzaglo D, Gazit E, Shimoni N, et al
Gait and heart rate: do they measure trait or state physical fatigue in people with multiple sclerosis?
J Neurol. 2024 May 2. doi: 10.1007/s00415-024-12339.
PubMed Abstract available

PREZIOSA P, Rocca MA, Filippi M
Radiologically isolated syndromes: to treat or not to treat?
J Neurol. 2024;271:2370-2378.
PubMed Abstract available

LEHNERER S, Herdick M, Stegherr R, Gerischer L, et al
Burden of disease in Lambert-Eaton myasthenic syndrome: taking the patient's perspective.
J Neurol. 2024;271:2824-2839.
PubMed Abstract available

KONEN FF, Jendretzky KF, Ratuszny D, Schuppner R, et al
Ravulizumab in myasthenic crisis: the first case report.
J Neurol. 2024;271:2898-2901.
PubMed

BURTON JM, Youn S, Al-Ani A, Costello F, et al
Patterns and utility of myelin oligodendrocyte glycoprotein (MOG) antibody testing in cerebrospinal fluid.
J Neurol. 2024;271:2662-2671.
PubMed Abstract available

HEIDER D, Stetefeld H, Meisel A, Bosel J, et al
POLAR: prediction of prolonged mechanical ventilation in patients with myasthenic crisis.
J Neurol. 2024;271:2875-2879.
PubMed

RISI M, Greco G, Masciocchi S, Rigoni E, et al
MOG-IgG testing strategies in accordance with the 2023 MOGAD criteria: a clinical-laboratory assessment.
J Neurol. 2024;271:2840-2843.
PubMed Abstract available

DOUBROVINSKAJA S, Korporal-Kuhnke M, Jarius S, Haas J, et al
Newly emerging type B insulin resistance (TBIR) during treatment with eculizumab for AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD): fatal outcome.
J Neurol. 2024;271:2866-2870.
PubMed Abstract available

ROCCA MA, Romano F, Tedone N, Filippi M, et al
Advanced neuroimaging techniques to explore the effects of motor and cognitive rehabilitation in multiple sclerosis.
J Neurol. 2024 May 1. doi: 10.1007/s00415-024-12395.
PubMed Abstract available

April 2024

DIMAURO KA, Swetlik C, Cohen JA
Management of multiple sclerosis in older adults: review of current evidence and future perspectives.
J Neurol. 2024 Apr 30. doi: 10.1007/s00415-024-12384.
PubMed Abstract available

ROSENSTEIN I, Nordin A, Sabir H, Malmestrom C, et al
Association of serum glial fibrillary acidic protein with progression independent of relapse activity in multiple sclerosis.
J Neurol. 2024 Apr 26. doi: 10.1007/s00415-024-12389.
PubMed Abstract available

FONTE J, Stabile A, de Curtis M, Di Giacomo R, et al
Seizures in autoimmune-associated epilepsy: a long-term video-EEG monitoring study.
J Neurol. 2024 Apr 24. doi: 10.1007/s00415-024-12385.
PubMed

NAUTA IM, van Dam M, Bertens D, Kessels RPC, et al
Improved quality of life and psychological symptoms following mindfulness and cognitive rehabilitation in multiple sclerosis and their mediating role for cognition: a randomized controlled trial.
J Neurol. 2024 Apr 23. doi: 10.1007/s00415-024-12327.
PubMed Abstract available

SPIEZIA AL, Scalia G, Petracca M, Caliendo D, et al
Effect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications.
J Neurol. 2024 Apr 17. doi: 10.1007/s00415-024-12362.
PubMed Abstract available

HIRT J, Dembowska K, Woelfle T, Axfors C, et al
Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis.
J Neurol. 2024 Apr 16. doi: 10.1007/s00415-024-12366.
PubMed Abstract available

SINGER BA, Feng J, Chiong-Rivero H
Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption.
J Neurol. 2024 Apr 14. doi: 10.1007/s00415-024-12305.
PubMed Abstract available

ZHANG Y, Liu D, Zhang Z, Huang X, et al
Bispecific BCMA/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report.
J Neurol. 2024 Apr 11. doi: 10.1007/s00415-024-12367.
PubMed

STALTER J, Pars K, Witt K
Accelerated long-term forgetting reveals everyday memory deficits in early-stage multiple sclerosis.
J Neurol. 2024 Apr 8. doi: 10.1007/s00415-024-12359.
PubMed Abstract available

MARTINEZ-MARTINEZ L, Lacruz AC, Querol L, Cortes-Vicente E, et al
Inter-laboratory comparison of routine autoantibody detection methods for autoimmune neuropathies and myasthenia gravis.
J Neurol. 2024 Apr 5. doi: 10.1007/s00415-024-12317.
PubMed Abstract available

CELIK M, Baba C, Irmak C, Ozakbas S, et al
Risk of hepatitis B virus reactivation in people with multiple sclerosis treated with ocrelizumab: an observational study from Turkey.
J Neurol. 2024 Apr 5. doi: 10.1007/s00415-024-12333.
PubMed Abstract available

STEFANOU MI, Giannopapas V, Kitsos DK, Chondrogianni M, et al
Prevalence and epidemiology of stroke in patients with multiple sclerosis: a systematic review and meta-analysis.
J Neurol. 2024 Apr 4. doi: 10.1007/s00415-024-12331.
PubMed Abstract available

TERAYAMA A, Kuwahara M, Yoshikawa K, Yamagishi Y, et al
Takotsubo cardiomyopathy in Guillain-Barre syndrome.
J Neurol. 2024 Apr 4. doi: 10.1007/s00415-024-12295.
PubMed Abstract available

MAIDA E, Moccia M, Palladino R, Borriello G, et al
ChatGPT vs. neurologists: a cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosis.
J Neurol. 2024 Apr 3. doi: 10.1007/s00415-024-12328.
PubMed Abstract available

SIGNORIELLO E, Foschi M, Lanzillo R, Frau J, et al
Pregnancy effect on disease activity in women with multiple sclerosis treated with cladribine.
J Neurol. 2024 Apr 3. doi: 10.1007/s00415-024-12291.
PubMed Abstract available

GUERRIERI S, Rubin M, Gattuso I, Zanetta C, et al
Can treatment adverse events be optimized by switching between different sphingosine 1-phosphate receptor modulators in multiple sclerosis? A case series.
J Neurol. 2024 Apr 2. doi: 10.1007/s00415-024-12342.
PubMed

MCWILLIAM O, Gramkow MH, Blaabjerg M, Clemmensen FK, et al
Differentiating anti-IgLON5 disease and Lewy body dementia: a systematic review.
J Neurol. 2024;271:1707-1716.
PubMed Abstract available

WANG Y, Hu C, Aljarallah S, Reyes Mantilla M, et al
Expanding clinical profiles and prognostic markers in stiff person syndrome spectrum disorders.
J Neurol. 2024;271:1861-1872.
PubMed Abstract available

TEDONE N, Vizzino C, Meani A, Gallo A, et al
The brief repeatable battery of neuropsychological tests (BRB-N) version a: update of Italian normative data from the Italian Neuroimaging Network Initiative (INNI).
J Neurol. 2024;271:1813-1823.
PubMed Abstract available

GLASER A, Butzkueven H, van der Walt A, Gray O, et al
Big Multiple Sclerosis Data network: an international registry research network.
J Neurol. 2024 Apr 1. doi: 10.1007/s00415-024-12303.
PubMed Abstract available

HUA T, Fan H, Duan Y, Tian D, et al
Spinal cord and brain atrophy patterns in neuromyelitis optica spectrum disorder and multiple sclerosis.
J Neurol. 2024 Apr 1. doi: 10.1007/s00415-024-12281.
PubMed Abstract available

March 2024

GUILLEMIN C, Vandeleene N, Charonitis M, Requier F, et al
Brain microstructure is linked to cognitive fatigue in early multiple sclerosis.
J Neurol. 2024 Mar 28. doi: 10.1007/s00415-024-12316.
PubMed Abstract available

SCHALLER-PAULE MA, Maiworm M, Schafer JH, Friedauer L, et al
Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury.
J Neurol. 2024 Mar 27. doi: 10.1007/s00415-024-12299.
PubMed Abstract available

MALLUCCI G, Ferraro OE, Trojano M, Amato MP, et al
Early prediction of unfavorable evolution after a first clinical episode suggestive of multiple sclerosis: the EUMUS score.
J Neurol. 2024 Mar 26. doi: 10.1007/s00415-024-12304.
PubMed Abstract available

ZHANG H, Ma J, Feng Y, Ma H, et al
Efgartigimod in the treatment of Guillain-Barre syndrome.
J Neurol. 2024 Mar 26. doi: 10.1007/s00415-024-12321.
PubMed Abstract available

FUCHS L, Shelly S, Vigiser I, Kolb H, et al
Real-World experience with efgartigimod in patients with myasthenia gravis.
J Neurol. 2024 Mar 25. doi: 10.1007/s00415-024-12293.
PubMed Abstract available

PILOTTO S, Floris M, Solla P, Pugliatti M, et al
Determinants of self-perceived quality of life in mildly disabled multiple sclerosis patients: a cross-sectional study.
J Neurol. 2024 Mar 25. doi: 10.1007/s00415-024-12244.
PubMed Abstract available

LAUVSNES MB, Zetterberg H, Blennow K, Kvaloy JT, et al
Correction to: Neurofilament light in plasma is a potential biomarker of central nervous system involvement in systemic lupus erythematosus.
J Neurol. 2024 Mar 23. doi: 10.1007/s00415-024-12238.
PubMed

GOERECI Y, Ellenberger D, Rommer P, Dunkl V, et al
Persons with multiple sclerosis older than 55 years: an analysis from the German MS registry.
J Neurol. 2024 Mar 22. doi: 10.1007/s00415-024-12286.
PubMed Abstract available

ALBERGONI M, Pagani E, Preziosa P, Meani A, et al
Thalamic nuclei volume partially mediates the effects of aerobic capacity on fatigue in people with multiple sclerosis.
J Neurol. 2024 Mar 20. doi: 10.1007/s00415-024-12277.
PubMed Abstract available

ABDELGAIED MY, Rashad MH, El-Tayebi HM, Solayman MH, et al
Correction to: The impact of metformin use on the outcomes of relapse?remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open?label randomized controlled trial.
J Neurol. 2024 Mar 18. doi: 10.1007/s00415-024-12249.
PubMed

VILASECA A, Farina A, Villagran-Garcia M, Pegat A, et al
Neurological autoimmunity in melanoma patients: a comparison between those exposed and non-exposed to immune checkpoint inhibitors.
J Neurol. 2024 Mar 11. doi: 10.1007/s00415-024-12252.
PubMed Abstract available

KRIJNEN EA, Broeders TAA, Noteboom S, van Dam M, et al
The cognitive relevance of non-lesional damage to cortical networks in people with multiple sclerosis.
J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12240.
PubMed Abstract available

HEGEN H, Berek K, Deisenhammer F, Berger T, et al
Sex impacts treatment decisions in multiple sclerosis.
J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12270.
PubMed Abstract available

HECHENBERGER S, Helmlinger B, Tinauer C, Jauk E, et al
Evaluation of a self-administered iPad((R))-based processing speed assessment for people with multiple sclerosis in a clinical routine setting.
J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12274.
PubMed Abstract available

ZID Y, Robertson NP
Extended interval dosing strategies in multiple sclerosis: insights from natalizumab and ocrelizumab trials.
J Neurol. 2024 Mar 4. doi: 10.1007/s00415-024-12273.
PubMed

LI J, Wu X, Chu T, Tan X, et al
The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis.
J Neurol. 2024 Mar 3. doi: 10.1007/s00415-024-12247.
PubMed Abstract available

GUGER M, Enzinger C, Leutmezer F, Di Pauli F, et al
Early intensive versus escalation treatment in patients with relapsing-remitting multiple sclerosis in Austria.
J Neurol. 2024 Mar 2. doi: 10.1007/s00415-024-12256.
PubMed Abstract available

February 2024

SCHERER L, Soudant M, Pittion-Vouyovitch S, Debouverie M, et al
Risk of secondary progression in patients with highly active multiple sclerosis treated with natalizumab: a real-life study.
J Neurol. 2024 Feb 29. doi: 10.1007/s00415-024-12266.
PubMed Abstract available

TOLJAN K, Briggs FBS
Male sexual and reproductive health in multiple sclerosis: a scoping review.
J Neurol. 2024 Feb 28. doi: 10.1007/s00415-024-12250.
PubMed Abstract available

LEAVITT VM, Tozlu C, Nelson KE, Boehme AK, et al
A randomized controlled trial of oral antipyretic treatment to reduce overheating during exercise in adults with multiple sclerosis.
J Neurol. 2024 Feb 28. doi: 10.1007/s00415-023-12147.
PubMed Abstract available

VAN DAM M, Krijnen EA, Nauta IM, Fuchs TA, et al
Identifying and understanding cognitive profiles in multiple sclerosis: a role for visuospatial memory functioning.
J Neurol. 2024 Feb 26. doi: 10.1007/s00415-024-12227.
PubMed Abstract available

NGUYEN TT, Chae J, Kang JJ, Oh SY, et al
Saccadic fatigue as an early indicator for diagnosing myasthenia gravis.
J Neurol. 2024 Feb 25. doi: 10.1007/s00415-024-12262.
PubMed

WEISS MD, Freimer M, Leite MI, Maniaol A, et al
Improvement of fatigue in generalised myasthenia gravis with zilucoplan.
J Neurol. 2024 Feb 24. doi: 10.1007/s00415-024-12209.
PubMed Abstract available

OHNARI K, Hashimoto T, Iwanaka Y, Ohnari K, et al
Dramatic improvement in refractory myasthenia gravis with eculizumab treatment: a case report.
J Neurol. 2024 Feb 23. doi: 10.1007/s00415-024-12245.
PubMed

GREGULETZ P, Plotz M, Baade-Buttner C, Bien CG, et al
Different pain phenotypes are associated with anti-Caspr2 autoantibodies.
J Neurol. 2024 Feb 22. doi: 10.1007/s00415-024-12224.
PubMed Abstract available

CUTILLO G, Rubin M, d'Amore G, Malcangi M, et al
Infratentorial posterior reversible encephalopathy syndrome in INFbeta1a-treated multiple sclerosis patient.
J Neurol. 2024 Feb 22. doi: 10.1007/s00415-024-12226.
PubMed

BIANCHI A, Matranga D, Patti F, Maniscalco L, et al
The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT).
J Neurol. 2024 Feb 16. doi: 10.1007/s00415-024-12214.
PubMed Abstract available

HARDING KE, Kreft KL, Ben-Shlomo Y, Robertson NP, et al
Prodromal multiple sclerosis: considerations and future utility.
J Neurol. 2024 Feb 11. doi: 10.1007/s00415-023-12173.
PubMed Abstract available

VANCURA J, Boyd NK, Vogel BN, Nagesh D, et al
Rapidly progressive moyamoya vasculopathy stabilized with immunotherapy in aicardi-goutieres syndrome.
J Neurol. 2024;271:1019-1022.
PubMed

January 2024

BAJRAMI A, Tamanti A, Peloso A, Ziccardi S, et al
Ocrelizumab reduces cortical and deep grey matter loss compared to the S1P-receptor modulator in multiple sclerosis.
J Neurol. 2024 Jan 30. doi: 10.1007/s00415-023-12179.
PubMed Abstract available

BOUMAN PM, van Dam MA, Jonkman LE, Steenwijk MD, et al
Isolated cognitive impairment in people with multiple sclerosis: frequency, MRI patterns and its development over time.
J Neurol. 2024 Jan 30. doi: 10.1007/s00415-024-12185.
PubMed Abstract available

NAUTA IM, Kessels RPC, Bertens D, Stam CJ, et al
Neurophysiological brain function predicts response to cognitive rehabilitation and mindfulness in multiple sclerosis: a randomized trial.
J Neurol. 2024 Jan 26. doi: 10.1007/s00415-024-12183.
PubMed Abstract available

CENSI S, Bisaccia G, Gallina S, Tomassini V, et al
Guillain-Barre syndrome and COVID-19 vaccination: a systematic review and meta-analysis.
J Neurol. 2024 Jan 17. doi: 10.1007/s00415-024-12186.
PubMed Abstract available

FENG G, Posa S, Sureshkumar A, Simpson S, et al
Experiences of people with multiple sclerosis and clinicians in using cognitive behavioural therapies for hidden symptoms: a systematic review and meta-aggregation.
J Neurol. 2024 Jan 14. doi: 10.1007/s00415-023-12116.
PubMed Abstract available

ZHENG P, Sandroff BM, Motl RW
Free-living ambulatory physical activity and cognitive function in multiple sclerosis: the significance of step rate vs. step volume.
J Neurol. 2024 Jan 12. doi: 10.1007/s00415-023-12169.
PubMed Abstract available

MAILLART E, Todesco E, Assoumou L, Beigneux Y, et al
Humoral response after accelerated schedule of HBV vaccination in MS patients before anti-CD20 therapy.
J Neurol. 2024 Jan 11. doi: 10.1007/s00415-023-12175.
PubMed

TRYFONOS C, Chrysafi M, Vadikolias K, Berberoglou L, et al
Nutritional interventional studies in patients with multiple sclerosis: a scoping review of the current clinical evidence.
J Neurol. 2024 Jan 4. doi: 10.1007/s00415-023-12140.
PubMed Abstract available

LOREFICE L, Ferraro OE, Fenu G, Amato MP, et al
Late-onset multiple sclerosis: disability trajectories in relapsing-remitting patients of the Italian MS Registry.
J Neurol. 2024 Jan 3. doi: 10.1007/s00415-023-12152.
PubMed Abstract available

FAVRUZZO F, Palmieri A, Giopato F, Cardellini D, et al
Subacute transverse myelitis of possible vasculitic origin after SARS-CoV2 and Varicella-Zoster virus infections: a case report.
J Neurol. 2024;271:75-78.
PubMed

NEUMANN B, Angstwurm K, Dohmen C, Mergenthaler P, et al
Weaning and extubation failure in myasthenic crisis: a multicenter analysis.
J Neurol. 2024;271:564-574.
PubMed Abstract available

WIESENFARTH M, Stamminger T, Zizer E, Tumani H, et al
Neurological manifestation of HEV infection: still a rare disease entity?
J Neurol. 2024;271:386-394.
PubMed Abstract available

MOSER T, Zimmermann G, Baumgartner A, Berger T, et al
Long-term outcome of natalizumab-associated progressive multifocal leukoencephalopathy in Austria: a nationwide retrospective study.
J Neurol. 2024;271:374-385.
PubMed Abstract available

KUMPFEL T, Giglhuber K, Aktas O, Ayzenberg I, et al
Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.
J Neurol. 2024;271:141-176.
PubMed Abstract available

December 2023

AZZIMONTI M, Margoni M, Zanetta C, Genovese F, et al
Tumefactive demyelinating lesions: a challenging first manifestation of multiple sclerosis.
J Neurol. 2023 Dec 28. doi: 10.1007/s00415-023-12164.
PubMed

LIU M, Ren H, Wang L, Fan S, et al
Prognostic and relapsing factors of primary autoimmune cerebellar ataxia: a prospective cohort study.
J Neurol. 2023 Dec 23. doi: 10.1007/s00415-023-12128.
PubMed Abstract available

IAFFALDANO P, Lucisano G, Guerra T, Patti F, et al
Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry.
J Neurol. 2023 Dec 22. doi: 10.1007/s00415-023-12137.
PubMed Abstract available

ANDORRA M, Freire A, Zubizarreta I, de Rosbo NK, et al
Predicting disease severity in multiple sclerosis using multimodal data and machine learning.
J Neurol. 2023 Dec 22. doi: 10.1007/s00415-023-12132.
PubMed Abstract available

MISTRI D, Valsasina P, Storelli L, Filippi M, et al
Monoaminergic network dysfunction and development of depression in multiple sclerosis: a longitudinal investigation.
J Neurol. 2023 Dec 19. doi: 10.1007/s00415-023-12138.
PubMed Abstract available

HABBESTAD A, Willumsen JS, Aarseth JH, Grytten N, et al
Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based study.
J Neurol. 2023 Dec 14. doi: 10.1007/s00415-023-12047.
PubMed Abstract available

COVEY TJ, Golan D, Sergott R, Wilken J, et al
Peering further into the mind's eye: combining visual evoked potential and optical coherence tomography measures enhances insight into the variance in cognitive functioning in multiple sclerosis.
J Neurol. 2023 Dec 13. doi: 10.1007/s00415-023-12075.
PubMed Abstract available

ARROYO PEREIRO P, Munoz-Vendrell A, Leon Moreno I, Bau L, et al
Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort.
J Neurol. 2023 Dec 12. doi: 10.1007/s00415-023-12135.
PubMed Abstract available

TSAI CC, Jette S, Tremlett H
Disease-modifying therapies used to treat multiple sclerosis and the gut microbiome: a systematic review.
J Neurol. 2023 Dec 11. doi: 10.1007/s00415-023-12107.
PubMed Abstract available

ABDELGAIED MY, Rashad MH, El-Tayebi HM, Solayman MH, et al
The impact of metformin use on the outcomes of relapse-remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open-label randomized controlled trial.
J Neurol. 2023 Dec 9. doi: 10.1007/s00415-023-12113.
PubMed Abstract available

November 2023

MEYER-ARNDT L, Brasanac J, Gamradt S, Bellmann-Strobl J, et al
Body mass, neuro-hormonal stress processing, and disease activity in lean to obese people with multiple sclerosis.
J Neurol. 2023 Nov 27. doi: 10.1007/s00415-023-12100.
PubMed Abstract available

MISTRI D, Tedone N, Biondi D, Vizzino C, et al
Cognitive phenotypes in multiple sclerosis: mapping the spectrum of impairment.
J Neurol. 2023 Nov 26. doi: 10.1007/s00415-023-12102.
PubMed Abstract available

JAKIMOVSKI D, Kavak KS, Coyle PK, Goodman AD, et al
Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium.
J Neurol. 2023 Nov 23. doi: 10.1007/s00415-023-12099.
PubMed Abstract available

BISECCO A, Matrone F, Capobianco M, De Luca G, et al
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients.
J Neurol. 2023 Nov 20. doi: 10.1007/s00415-023-12084.
PubMed Abstract available

SUN Y, Li G, Liu X, Zhao X, et al
Cerebral glucose hypometabolism and hypoperfusion of cingulate gyrus: an imaging biomarker of autoimmune encephalitis with psychiatric symptoms.
J Neurol. 2023 Nov 9. doi: 10.1007/s00415-023-12051.
PubMed Abstract available

KENNEDY PGE, George W, Yu X
The elusive nature of the oligoclonal bands in multiple sclerosis.
J Neurol. 2023 Nov 9. doi: 10.1007/s00415-023-12081.
PubMed Abstract available

DI FILIPPO M, Ferraro D, Ragonese P, Prosperini L, et al
SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose.
J Neurol. 2023 Nov 3. doi: 10.1007/s00415-023-12034.
PubMed Abstract available

FROHLICH K, Mrochen A, Wang R, Haupenthal D, et al
Cerebral lesions sites in neurosarcoidosis: a lesion mapping study.
J Neurol. 2023;270:5392-5397.
PubMed Abstract available

JEANTIN L, Shor N, Pallix-Guyot M, Roos-Weil D, et al
Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod.
J Neurol. 2023 Nov 1. doi: 10.1007/s00415-023-12055.
PubMed

October 2023

MANTERO V, Cordano C, Balgera R, Basilico P, et al
Serum sickness in a multiple sclerosis patient treated with ocrelizumab.
J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-12082.
PubMed

KAPPOS L, Traboulsee A, Li DKB, Bar-Or A, et al
Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension.
J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-11943.
PubMed Abstract available

DELGADO SR, Faissner S, Linker RA, Rammohan K, et al
Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment.
J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-12007.
PubMed Abstract available

RIVEL M, Achiron A, Stern Y, Zeilig G, et al
Emotional burden among MS patients: associations between specific chronic pain diagnoses and psychological features.
J Neurol. 2023 Oct 24. doi: 10.1007/s00415-023-12048.
PubMed Abstract available

ONTANEDA D, Chitnis T, Rammohan K, Obeidat AZ, et al
Identification and management of subclinical disease activity in early multiple sclerosis: a review.
J Neurol. 2023 Oct 21. doi: 10.1007/s00415-023-12021.
PubMed Abstract available

ZINGANELL A, Gobel G, Berek K, Hofer B, et al
Multiple sclerosis in the elderly: a retrospective cohort study.
J Neurol. 2023 Oct 19. doi: 10.1007/s00415-023-12041.
PubMed Abstract available

SELMAJ K, Cree BAC, Barnett M, Thompson A, et al
Multiple sclerosis: time for early treatment with high-efficacy drugs.
J Neurol. 2023 Oct 18. doi: 10.1007/s00415-023-11969.
PubMed Abstract available

RAVANO V, Piredda GF, Krasensky J, Andelova M, et al
Tract-wise microstructural analysis informs on current and future disability in early multiple sclerosis.
J Neurol. 2023 Oct 11. doi: 10.1007/s00415-023-12023.
PubMed Abstract available

MANZANO GS, McEntire C, Venna N
Case report of palatal tremor as a feature of CASPR2 autoimmune encephalitis.
J Neurol. 2023 Oct 11. doi: 10.1007/s00415-023-11992.
PubMed

ZHANG Z, Wang Z, Du X, Huang X, et al
Refractory generalized myasthenia gravis treated successfully with telitacicept: two cases report.
J Neurol. 2023 Oct 7. doi: 10.1007/s00415-023-12036.
PubMed

KRAKER JA, Chen JJ
An update on optic neuritis.
J Neurol. 2023;270:5113-5126.
PubMed Abstract available

BRISCA G, Marini C, Buratti S, Mariani M, et al
Acute pediatric encephalitis: etiology, course, and outcome of a 12-year single-center immunocompetent cohort.
J Neurol. 2023;270:5034-5047.
PubMed Abstract available

WANG R, Sun D, Du Q, Shi Z, et al
Satralizumab as a treatment for pediatric-onset neuromyelitis optica spectrum disorder with cluster attack: a case report.
J Neurol. 2023;270:5085-5089.
PubMed

September 2023

RODRIGUEZ DE VERA GOMEZ P, Mendez Muros M, Torres Cuadro A, Toyos Saenz de Miera FJ, et al
Alemtuzumab induces severe orbitopathy in relapsing-remitting multiple sclerosis.
J Neurol. 2023 Sep 29. doi: 10.1007/s00415-023-11995.
PubMed Abstract available

LI Y, Saul A, Taylor B, Ponsonby AL, et al
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies.
J Neurol. 2023 Sep 28. doi: 10.1007/s00415-023-11980.
PubMed Abstract available

KERNER C, Kotobelli K, Appleby BS, Cohen ML, et al
Pathological findings in autoimmune encephalitis autopsy specimens from cases of suspected prion disease.
J Neurol. 2023 Sep 27. doi: 10.1007/s00415-023-12003.
PubMed Abstract available

WEEDA MM, van Nederpelt DR, Twisk JWR, Brouwer I, et al
Multimodal MRI study on the relation between WM integrity and connected GM atrophy and its effect on disability in early multiple sclerosis.
J Neurol. 2023 Sep 17. doi: 10.1007/s00415-023-11937.
PubMed Abstract available

FILIPPI M, Grimaldi L, Conte A, Totaro R, et al
Intravenous or subcutaneous natalizumab in patients with relapsing-remitting multiple sclerosis: investigation on efficiency and savings-the EASIER study.
J Neurol. 2023 Sep 16. doi: 10.1007/s00415-023-11955.
PubMed Abstract available

GRIFFITH SP, Wesselingh R, Seery N, Rushen T, et al
Characterizing cognitive function in patients with autoimmune encephalitis: an Australian prospective study.
J Neurol. 2023 Sep 14. doi: 10.1007/s00415-023-11967.
PubMed Abstract available

MCARTHUR C, Daruwalla C, Jayeskara M, Brown JWL, et al
Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis.
J Neurol. 2023 Sep 12. doi: 10.1007/s00415-023-11984.
PubMed

DI STEFANO V, Alonge P, Rini N, Militello M, et al
Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome.
J Neurol. 2023 Sep 8. doi: 10.1007/s00415-023-11970.
PubMed Abstract available

JACOBS BM, Tank P, Bestwick JP, Noyce AJ, et al
Modifiable risk factors for multiple sclerosis have consistent directions of effect across diverse ethnic backgrounds: a nested case-control study in an English population-based cohort.
J Neurol. 2023 Sep 7. doi: 10.1007/s00415-023-11971.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.